Genetic validation of whole-transcriptome sequencing for mapping expression affected by cis-regulatory variation
- Equal contributors
1 Merck Research Laboratories, Research Informatics, 33 Avenue Louis Pasteur, Boston, MA, 02115, USA
2 Rosetta Inpharmatics, LLC, a wholly owned subsidiary of Merck & Co., Inc., 401 Terry Ave N, Seattle, WA, 98109, USA
3 University of Wisconsin-Madison, Department of Biochemistry, 433 Babcock Drive, Madison, WI, 53706, USA
4 Currently at Department of Biology, Stanford University, 371 Serra Mall, Stanford, CA, 94305, USA
5 Currently at Pacific Biosciences, 1505 Adams Drive, Menlo Park, CA, 94025, USA
6 Currently at NuGEN Technologies, 201 Industrial Road, San Carlos, CA 94070, USA
BMC Genomics 2010, 11:473 doi:10.1186/1471-2164-11-473Published: 13 August 2010
Identifying associations between genotypes and gene expression levels using microarrays has enabled systematic interrogation of regulatory variation underlying complex phenotypes. This approach has vast potential for functional characterization of disease states, but its prohibitive cost, given hundreds to thousands of individual samples from populations have to be genotyped and expression profiled, has limited its widespread application.
Here we demonstrate that genomic regions with allele-specific expression (ASE) detected by sequencing cDNA are highly enriched for cis-acting expression quantitative trait loci (cis-eQTL) identified by profiling of 500 animals in parallel, with up to 90% agreement on the allele that is preferentially expressed. We also observed widespread noncoding and antisense ASE and identified several allele-specific alternative splicing variants.
Monitoring ASE by sequencing cDNA from as little as one sample is a practical alternative to expression genetics for mapping cis-acting variation that regulates RNA transcription and processing.